FindTrial
Sign In

Efficacy Of Haridradi Anjana In Kaphaja Abhisyanda wsr Vernal Keratoconjunctivitis

Efficacy Of Haridradi Anjana In Kaphaja Abhisyanda (Vernal Keratoconjunctivitis) - EOHAIKAVK

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/025919
Enrollment
30
Registered
2020-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H00-H59- Diseases of the eye and adnexa

Interventions

None listed

Sponsors

Uttrakhand Ayurveda University Harrawala dehradun
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1-Patients aged between 8-20 years. 2-Patients, presenting with signs and symptoms of Kaphaja Abhishyanda /Vernal keratoconjunctivitis. 3-Sex -Either sex

Exclusion criteria

Exclusion criteria: 1-Patients having other eye diseases like blepharitis, trachoma, dry eye, corneal xerosis,phlyctenular keratoconjunctivitis, corneal ulcer, dacryocystitis, and infective conjunctivitis. 2-Patients suffering from other systemic disease & metabolic disorders.

Design outcomes

Primary

MeasureTime frame
Cured: 91% relief in signs and symptoms and no recurrence during follow up study. 2. Marked Improvement: 76-90% improvement in signs and symptoms. 3. Moderate Improvement: 51-75% improvement in signs and symptoms. 4. Mild Improvement: 26-50% improvement in signs and symptoms. 5. Unchanged: Up to or25% relief in signs and symptoms. Timepoint: 15 April 2021—

Secondary

MeasureTime frame
excerbation in sign and symptomTimepoint: 1 month—

Countries

India

Contacts

Public ContactEkta Ramola

Rishikul Ayurvedic Medical College

chauhanpriyanka40@gmail.com7500402154

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026